BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18776074)

  • 1. Quality of diabetes care among patients managed by teleconsultation.
    Nikkanen T; Timonen M; Ylitalo K; Timonen O; Keinänen-Kiukaanniemi S; Rajala U
    J Telemed Telecare; 2008; 14(6):295-9. PubMed ID: 18776074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
    Kooy A; de Jager J; Lehert P; Bets D; Wulffelé MG; Donker AJ; Stehouwer CD
    Arch Intern Med; 2009 Mar; 169(6):616-25. PubMed ID: 19307526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus.
    Al Mazroui NR; Kamal MM; Ghabash NM; Yacout TA; Kole PL; McElnay JC
    Br J Clin Pharmacol; 2009 May; 67(5):547-57. PubMed ID: 19552750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Quality of the treatment of type 2 diabetes: results from the GIANTT project 2004-2007].
    Voorham J; Haaijer-Ruskamp FM; van der Meer K; de Zeeuw D; Wolffenbuttel BH; Hoogenberg K; Denig P
    Ned Tijdschr Geneeskd; 2010; 154():A775. PubMed ID: 20132579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
    Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
    Davis TM; Cull CA; Holman RR;
    Diabetes Care; 2001 Jul; 24(7):1167-74. PubMed ID: 11423497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nurse-led cardiovascular risk factor intervention leads to improvements in cardiovascular risk targets and glycaemic control in people with Type 1 diabetes when compared with routine diabetes clinic attendance.
    Wallymahmed ME; Morgan C; Gill GV; Macfarlane IA
    Diabet Med; 2011 Mar; 28(3):373-9. PubMed ID: 21204963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study.
    Janssen PG; Gorter KJ; Stolk RP; Rutten GE
    Br J Gen Pract; 2009 Jan; 59(558):43-8. PubMed ID: 19105915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 diabetes in primary care in belgium: need for structured shared care.
    Goderis G; Borgermans L; Heyrman J; Broeke CV; Grol R; Boland B; Mathieu C
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):367-72. PubMed ID: 19358093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus.
    Abbasi F; Chu JW; McLaughlin T; Lamendola C; Leary ET; Reaven GM
    Metabolism; 2004 Feb; 53(2):159-64. PubMed ID: 14767866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
    Wulffelé MG; Kooy A; de Zeeuw D; Stehouwer CD; Gansevoort RT
    J Intern Med; 2004 Jul; 256(1):1-14. PubMed ID: 15189360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
    Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
    Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
    Diabetes Care; 2004 Jan; 27(1):41-6. PubMed ID: 14693964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
    Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.